Tianjin Pharma Da Ren Tang Sees Estimated 180%-204% Profit Surge to RMB2B in 1H25 on Disposal Gains
Summary:
-
Net profit attributable to equity holders for 1H FY2025 estimated at RMB1,840M–RMB2,000M, a jump of 180%–204% over RMB658M in 1H FY2024, mainly from the disposal of its final 12% stake in Tianjin TSKF Pharmaceutical, yielding an after-tax gain of about RMB1.31B.
-
Core profit (after deducting non-recurring items) expected at RMB560M–RMB620M, reflecting a 12%–2% decrease from RMB634M last year, due to loss of TSKF investment income that contributed ~RMB110M in 1H FY2024.
-
Without that prior TSKF income, adjusted recurring profit would show a year-on-year increase.
-
Earnings per share for 1H FY2024 was RMB0.85; updated EPS will be provided with the upcoming interim report.
-
Figures are based on unaudited internal estimates, with full results to be disclosed later. Investors advised to exercise caution.